Ensemble and Solventum Partner to Advance Autonomous Inpatient Coding with AI

/EIN News/ -- CINCINNATI, Ohio and ST. PAUL, Minn., May 20, 2025 (GLOBE NEWSWIRE) -- Ensemble, an industry leading revenue cycle management company, announced a strategic partnership today with Solventum, a market leader and innovator in AI-driven revenue cycle solutions. The partnership seeks to enable the first-of-its-kind autonomous coding solution at scale across all medical specialties, including inpatient services. This collaboration combines Solventum’s latest AI solutions and over 40 years of coding and compliance expertise with Ensemble’s operational scale and denial intelligence to automate accurate coding and prevent revenue loss with greater precision for hospitals nationwide. 

“Our collaboration with Ensemble represents a significant step forward in the evolution of autonomous coding,” said Garri Garrison, president of Solventum Health Information Systems. “By leveraging Ensemble’s extensive network and actionable insights, we are poised to rapidly evolve AI capable of addressing even the most complex specialties like inpatient claims. This helps ensure that providers benefit from precise, efficient coding processes while maintaining the highest standards of compliance and reimbursement accuracy."

Leveraging​ Solventum’s established autonomous coding capabilities, this partnership aims to develop the first comprehensive, end-to-end autonomous coding solution to support all medical specialties, including hospital-based inpatient claims, with precision and compliance. Ensemble plans to implement this advanced solution across its client base of 28 health systems, representing $40 billion in net patient revenue. The insights generated from this collaboration are expected to drive continuous refinement of coding algorithms and strengthen denial prevention strategies.

"We’re proud to partner with Solventum on our journey to eliminate friction in healthcare,” said Judson Ivy, Founder and CEO of Ensemble. “This strategic partnership underscores our commitment to responsibly integrating AI solutions to amplify success for our clients across the entire revenue cycle. By incorporating Solventum’s innovative technology and strong history of coding compliance into our suite of interconnected AI capabilities, we aim to create a seamlessly orchestrated revenue cycle. These solutions will empower our operators to concentrate on complex case reviews rather than administrative tasks, ultimately enhancing claim precision and improving revenue accuracy for hospitals and health systems.”

This partnership underscores the shared vision of Ensemble and Solventum to streamline revenue cycle management through AI-driven solutions. Together, they are poised to empower healthcare providers to focus more on delivering quality patient care while alleviating administrative burdens, ensuring a future where innovation drives better outcomes for both providers and patients.

About Ensemble

Ranked #1 revenue cycle management partner consistently by providers, Ensemble manages end-to-end revenue cycle operations for 28 health systems nationwide. Through a combination of certified revenue cycle operators, data-rich intelligence and advanced AI, Ensemble helps healthcare organizations sustain best-practice revenue cycle operations and maximize their current technology, so providers can focus on delivering exceptional care in their communities.

For more information, visit EnsembleHP.com or contact media@ensemblehp.com.

About Solventum 

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com

Contact news@solventum.com

This news release contains forward-looking information about Solventum’s financial results and estimates and business prospects, including guidance for 2025, that contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially from those described in our forward looking statements are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum’s control; (2) operational execution risks; (3) damage to Solventum’s reputation or its brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events, including the divestiture of our Purification and Filtration business; (5) Solventum’s business dealings involving third-party partners in various markets; (6) Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers’ research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as “PFAS”; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum’s failure to obtain, maintain, protect, or effectively enforce its intellectual property rights; (21) pension and postretirement obligation liabilities; (22) any failure by 3M Company (“3M”) to perform any of its obligations under the various separation agreements entered into in connection with the separation of Solventum from 3M and distribution (the “Spin-Off”); (23) any failure to realize the expected benefits of the Spin-Off; (24) a determination by the IRS or other tax authorities that the Separation or certain related transactions should be treated as taxable transactions; (25) indebtedness incurred in the financing transactions undertaken in connection with the Separation and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum's estimates; and (27) the impact of the Spin-Off on Solventum’s businesses and the risk that the separation from 3M may be more difficult, time-consuming or costly than expected, including the impact on Solventum's resources, systems, procedures and controls, diversion of management’s attention and the impact on relationships with customers, suppliers, employees and other business counterparties.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

Kendall Herold
                    Ensemble Health Partners
                    704-765-3715
                    Kendall.Herold@ensemblehp.com
                    
                    BPD Healthcare
                    Ensemble Health Partners
                    (615) 742-7242
                    ensemble@bpdhealthcare.com